(Q46733372)

24 December 2017

title

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer (English)

1 reference

24 December 2017

1 reference

10

Gabriel N Hortobagyi

1 reference

24 December 2017

Bita Esmaeli

9

object named as

Bita Esmaeli

1 reference

24 December 2017

author name string

Edgardo Rivera

1

1 reference

24 December 2017

Jaime A Mejia

2

1 reference

24 December 2017

Banu K Arun

3

1 reference

24 December 2017

Rosnie B Adinin

4

1 reference

24 December 2017

Ronald S Walters

5

1 reference

24 December 2017

Abenaa Brewster

6

1 reference

24 December 2017

Kristine R Broglio

7

1 reference

24 December 2017

Guosheng Yin

8

1 reference

24 December 2017

Vicente Valero

11

1 reference

24 December 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

24 December 2017

published in

Cancer

1 reference

24 December 2017

volume

112

1 reference

24 December 2017

issue

7

1 reference

24 December 2017

page(s)

1455-1461

1 reference

24 December 2017

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Signal transduction pathways of taxanes-induced apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Docetaxel for treatment of solid tumours: a systematic review of clinical data

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Adjuvant docetaxel for node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Which one is better: AIDS related or HIV associated?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.23321

7 January 2021

Identifiers

DOI

10.1002/CNCR.23321

1 reference

24 December 2017

1 reference

24 December 2017